Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

Top Cited Papers
Publisher Website
Google Scholar
Abstract
Detection of replication-competent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the most reliable indicator of contagiousness.1 Although the duration of live-virus shedding is well-characterized in immunocompetent patients with coronavirus disease 19 (Covid-19), little is known about how long immunocompromised patients are contagious. Consequently, the Centers for Disease Control and Prevention (CDC) guidelines on transmission-based precautions for immunocompromised patients are based on limited data.2
Funding Information
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases (CEIRS, contract # HHSN272201400008C)
  • JPB Foundation (2020-215611 (5384))
  • Center for Scientific Review (P01 CA23766, numbers S10OD018522 and S10OD026880)
  • Robin Chemers Neustein Postdoctoral Fellowship Award.
  • NIH/NCI (P30 CA008748)

This publication has 1 reference indexed in Scilit: